1. Home
  2. Faculty

Praveen Vikas, MBBS

Clinical Associate Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation

Current Positions

  • Clinical Associate Professor of Internal Medicine-Hematology, Oncology, and Blood & Marrow Transplantation

Education

  • MBBS, NHL Municipal Medical College, Gujarat University, Ahmedbad, India
  • Resident, Internal Medicine, East Tennessee State University, Johnson City, Tennessee
  • Fellow, Medical Oncology, East Tennessee State University, Johnson City, Tennessee

Selected Publications

  • Vikas P, Korde LA, Somerfield MR, Hershman DL. Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2022 Jun 21;OP2200284. doi: 10.1200/OP.22.00284 PMID: 35728019
  • Vikas, P., Borcherding, N. & Zhang, W. (2018). The clinical promise of immunotherapy in triple-negative breast cancer. Cancer management and research 10 6823-6833. DOI: 10.2147/CMAR.S185176. PMID: 30573992. PMCID: PMC6292225.
  • Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020 Apr 28;10:570. PMID: 32457830
  • Henry NL, Somerfield MR, Abramson VG, Ismaila N, Allison, KH, Anders CK, Chingos DT, Eisen A, Ferrari BL, Openshaw TH, Spears PA, Vikas P, Stearns V. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.  J Clin Oncol. 2019 Aug 1;37(22):1965-1977. PMID: 31206315
  • Borcherding, N., Kolb, R., Gullicksrud, J., Vikas, P., Zhu, Y. & Zhang, W. (2018). Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. Journal of molecular biology 430 (14) 2014-2029. DOI: 10.1016/j.jmb.2018.05.030. PMID: 29800567.
  • Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Dec 10;39(35):3959-3977. PMID: 34324367
  • Borcherding N, Jethava Y, Vikas P. Repurposing Anti-Cancer Drugs for COVID-19 Treatment. Drug Des Devel Ther. 2020 Nov 18;14:5045-5058. PMID: 33239864
  • Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song J-M, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology 2021 39:36, 4073-4126. PMID: 34724392
  • Gilbertson-White, S., Yeung, C. W., Saeidzadeh, S., Tykol, H., Vikas, P. & Cannon, A. (2018). Engaging Stakeholders in the Development of an eHealth Intervention for Cancer Symptom Management for Rural Residents. The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association. DOI: 10.1111/jrh.12297. PMID: 29696696.
  • Charlton, M., Schlichting, J., Chioreso, C., Ward, M. & Vikas, P. (2015). Challenges of Rural Cancer Care in the United States. Oncology (Williston Park, N.Y.) 29 (9) 633-40. PMID: 26384798.